

Strategic Isolation of API Synthetic Intermediates Using Crystal16 and Crystalline

Martin Glavinović • Bahareh Khalili

Our Growth Story







3

Alphora's Experience in Numbers

Strong Analytical to Process Chemistry Team 1:1 Ratio

> Over 200 Employees 79% Scientists 25% PhD 25% MSc 29% BSc

3 Self-held Drug Master File across a range of countries i.e. US, Canada, China, Japan, EU

Experience with Complex Chemistry One molecule with 75 conversions and 19 chiral centers

🔅 eurofins

CDMO

Developed 100s of compounds, for pre-clinical and clinical

Technology transfer of over 500 unique processes

Over 1200 Batches, Over 70 APIs

Validated processes for 6 Commercial APIs; 7 remain on the market; 6 active

6 FDA Approvals 2 Breakthrough/ Fast Track Programs

Our science is your success.



Solid State R&D Overview

Provide expertise and services in physicochemical characterization of API, intermediates as well as screening for different API solid forms and salts. Offer quality-by-design approach for small molecule APIs at different phases of pharmaceutical development.

High-Throughput Screening

Screening for discovery of new polymorphs, pharmaceutical salts, solvates, co-crystals, etc. using minimal amount of API



CDMO

Characterization

Complete physicochemical characterization of APIs and advanced intermediates utilizing state-of-the-art instrumentation.



Crystallization Engineering

Optimized crystallization and scale-up through crystal engineering and inline monitoring techniques.



Solid Form in Pharma Industry

- Polymorphs are crystalline materials composed of the same molecules, but with a different packing structure.
- 90% of active pharmaceutical ingredients (APIs) show polymorphism Acetaminophen – 3 polymorphic forms
 Atorvastatin – 60 solid forms
 Ritonavir – 5 polymorphic forms
 Axitinib – 60 solid forms
- Polymorphism (APIs/ intermediates) directly affect the manufacturing process and final product:
 - Solubility Reactivity and yield

🔅 eurofins

- Morphology & particle size Filtration and drying
- Occlusion & inclusion Impurity purge and solvent levels
- Hygroscopicity Stability and storage







Effect of Process Parameters on Polymorphism and Particle Size

- Solvent composition.
- Isolation temperature. Cooling/heating rates.
- Seeding
- Mechanical activation of the solid substance
- Exposure to vapor at high or low humidity
- Exposure to organic vapor



Introduction



- PhD Chemist with experience in porous solids and gas separations.
- Worked on this project between May 2023-Sep 2023.
- First time using Crystal 16 and more recently, Crystalline.
 - Instruments are easy to use.
 - Intuitive workflows.
 - In short: Someone who's relatively inexperienced can use these instruments and get a lot of useful information.

Introduction



- Multi-step synthesis of API.
- Compounds I and II are approx. 500-600 g/mol, $C_xH_yCl_zN_\alpha O_\beta$, couple aryl rings, flexible molecule.
- Challenge: Optimize crystallization protocols to isolate the desired products from their respective reaction mixtures.
- Targeted high yields, good crystal quality (large crystals, high purity), simple procedure.







Case Study I: Part I MIBK/Heptane

- One solid form of Compound I was discovered during development process.
- Isolation from various solvents was possible. Methyl iso-butyl ketone (MIBK) with heptane anti-solvent was a reasonable choice.
- Solubility curves of crystalline Compound I collected using Crystal 16. Compounds heated from 20 to 70 °C at 0.5 °C/min, held for 15 minutes, cooled to -5 °C at 0.1 °C/min. Held for 12 hours.
- Note: curves extrapolated from experimental data using Van't Hoff equation.





Case Study I: Part I MIBK/Heptane

• Input:

- Supersaturated organic fraction with approximately
 5g of product dissolved in 20 mL MIBK.
- The first plan:
 - 2. Seed with crystalline compound I.
 - 3. Add heptane anti-solvent.
- Theoretical yield: 96%



Polarized Microscope Images: 10x and 40x magnification

Figure – Solubility curves compound I (MIBK/Heptane). 300 O Start 250 1 200 Concentratrion (mg/mL) 00 05 2 50 3 End 0 10 50 20 30 40 60 70 80 0 Temp (°C) — MIBK extrapolated MIBK 2:1 MIBK/Heptane 2:1 MIBK/Heptane extrapolated • 1:1 MIBK/Heptane • 1:2 MIBK/Heptane



Case Study I: Part I MIBK/Heptane

• Input:

- Supersaturated organic fraction with approximately 5g of solid dissolved in 20 mL MIBK.
- The second plan:
 - 2. Heat to 50 °C.
 - 3. Seed with crystalline compound I to induce crystallization.
 - 4. Wait for product to desaturate from solution. Perform crystal growth at warm temperature. Promotes larger/higher quality crystals.
 - 5. Cool slowly (0.5 °C/min)
 - 6. Add anti-solvent portionwise.

Figure – Solubility curves compound I (MIBK/Heptane). 300 2 250 200 Concentratrion (mg/mL) 00 05 3 4 5 50 6 0 10 20 30 40 50 60 70 80 0 Temp (°C) ----- MIBK extrapolated MIBK 2:1 MIBK/Heptane 2:1 MIBK/Heptane extrapolated 1:1 MIBK/Heptane • 1:2 MIBK/Heptane



Case Study I: Part I MIBK/Heptane In-line FBRM probe and supplementary PLM

Figure – FBRM monitored crystallization of compound I. Measuring chord length vs Time. <10 μ m | 10-50 μ m | 50-1000 μ m | Mean sqr.





IPC #1 10 x magnification



IPC #2 4 x magnification



IPC #3 4 x magnification



- Isolation in MIBK/Heptane was successful. Possible to improve?
- Isolation requires a solvent swap to MIBK. Is it possible to isolate from reaction solvent?
- Reaction was performed in MeOH.
- Quenching with aqueous solution of acetic acid resulted in the precipitation of the product in high purity.
- Challenge: Optimize the recrystallization directly from reaction mixture.



- Challenge: Optimize the recrystallization directly from reaction mixture.
- Solubility curves of crystalline Compound I collected using Crystal 16. Compounds heated from 20 to 50 °C at 0.5 °C/min, held for 15 minutes, cooled to 5 °C at 0.1 °C/min. Held for 12 hours.
- Note: curves extrapolated using Van't Hoff equation.

Figure – Solubility curves compound I (MeOH/water). 200 180 160 140 Concentratrion (mg/mL) 120 100 80 60 40 20 0 30 10 20 40 50 60 0 Temp (°C) ---- MeOH extrapolated MeOH -4:1 MeOH/water extrapolated ▲ 4:1 MeOH/water ▲ 2:1 MeOH/water



• Input:

1. Organic fraction with 5g of product in 50 mL MeOH.

Solubility of Compound I is high. Need to add water anti-solvent first to crystallize product.

Addition of water has a significant oiling out risk. This was monitored in-situ using Crystalline.

Figure – Solubility curves compound I (MeOH/water). 200 180 160 140 Concentratrion (mg/mL) 120 100 80 60 40 20 0 30 10 20 40 50 60 0 Temp (°C) -----MeOH extrapolated ▲ MeOH -4:1 MeOH/water extrapolated ▲ 4:1 MeOH/water ▲ 2:1 MeOH/water



Case Study I: Part 2 MeOH/water Monitoring anti-solvent additions with Crystalline





• Input:

- Organic fraction with 5g of product dissolved in 50 mL MeOH.
- The first plan:
 - 2. Add water to obtain a metastable 4:1 MeOH/water mixture.
 - 3. Seed at 25 °C
 - 4. Cool slowly to 5 °C (0.5 °C/min)
 - 5. Add water to obtain a 2:1 MeOH/water mixture.

Figure – Solubility curves compound I (MeOH/water). 200 180 160 140 Concentratrion (mg/mL) 120 100 2 80 60 3 40 4 20 5 0 30 40 10 20 50 60 0 Temp (°C) ---- MeOH extrapolated ▲ MeOH -4:1 MeOH/water extrapolated ▲ 4:1 MeOH/water ▲ 2:1 MeOH/water



• Input:

- Organic fraction with 5g of product dissolved in 50 mL MeOH.
- The second plan:
 - 2. Add water to obtain an oiled out 2:1 MeOH/water mixture.
 - 3. Heat until complete dissolution (60 °C)
 - 4. Cool slowly to 45 °C to obtain a metastable solution.
 - 5. Seed at 45 °C.
 - Wait for product to desaturate from solution. Perform crystal growth at warm temperature.
- 7. Cool slowly to 25 °C (0.5 °C/min)

Figure – Solubility curves compound I (MeOH/water). 200 180 160 140 Concentratrion (mg/mL) 120 100 80 3, 4 2 60 5, 6 40 7 20 0 30 10 20 40 50 60 0 Temp (°C) ---- MeOH extrapolated ▲ MeOH ▲ 4:1 MeOH/water -4:1 MeOH/water extrapolated ▲ 2:1 MeOH/water



Case Study I: Part 2 MeOH/water Monitoring seeded **4:1 MeOH/water** with Crystalline



🔅 eurofins

CDMO



19



Case Study I: Part 2 MeOH/water Monitoring seeded **4:1 MeOH/water** with Crystalline







Case Study I: Part 2 MeOH/water Monitoring seeded 2:1 MeOH/water with Crystalline







Case Study I: Part 2 MeOH/water Monitoring seeded 2:1 MeOH/water with Crystalline







Case Study I Comparison of **4:1** and **2:1** MeOH/water crystallizations





4:1 MeOH/water isolated product PLM images





2:1 MeOH/water isolated product PLM images 10x and 40x magnification



4:1 MeOH/water UPLC: 100.0% product Isolated yield: 77.7%

2:1 MeOH/water UPLC: 100.0% product Isolated yield: 80.9%

Figure – PXRD patterns of compound I.

CDMO

Simulated from SCXRD | 4:1 MeOH/water recrystallization | 2:1 MeOH/water recrystallization

😵 eurofins

Counts



Case Study I Conclusions

- MIBK/Heptane: Much higher quality crystals of compound I were grown using the higher temperature crystallization,
- 100 kg scale synthesis of compound I was performed. Using the MIBK/Heptane crystallization protocol developed at Eurofins Alphora resulted in a yield of 85%.
- MeOH/water: In-situ monitoring using Crystalline revealed the significant oiling risk of Compound I from MeOH/water. The solubility curves from Crystal 16, coupled with in-situ monitoring using Crystalline, allowed us to rapidly develop two crystallizations procedures in which we could maneuver around this hazard.
- Optimization of MeOH/water isolation will be the focal point of the next campaign.
- In-house we performed a 100g scale reaction using the 2:1 MeOH/water isolation, obtaining a yield of 80%.



Case Study II

- Two solid forms (Form A and B) of Compound II 3000 6000 9000 were discovered and Counts structurally characterized during development. 2Theta (Coupled TwoTheta/Theta) WL=1.54056 Figure – Simulated PXRD patterns of Compound II Form A | Form B $\Delta H = 36.3 J/g$ DSC reveals that Form B Peak onset: 89.19 °C 20 mW has slightly higher Peak Maximum: 95.00 °C stability.
 - Figure DSC thermograms of Compound II





Case Study II: MTBE/Heptane

- Solubility curves of crystalline Compound II Form A and B were collected using Crystal 16. Compounds heated from 20 to 70 °C at 0.5 °C/min, held for 15 minutes, cooled to -5 °C at 0.1 °C/min. Held for 12 hours.
- Trace water increases solubility.
- Form B is consistently less soluble.
- Isolation was attempted by seeding with different forms.



Figure – Solubility curves compound II (MTBE/heptane).



Case Study II: MTBE/Heptane Seeding Form A Figure – Solut

Figure – Solubility curves compound II (MTBE/heptane).

Input:

🔅 eurofins

- 1. Organic fraction with 0.6 g of product dissolved in 3 mL MTBE saturated with water.
- Plan to seed form A:
 - 2. Cool to 15 °C to make a metastable solution.
 - 3. Seed at 15 °C.
 - 4. Grow crystals at 15 °C.
 - 5. Cool slowly to 0 °C (0.5 °C/min)





Case Study II: MTBE/Heptane Seeding Form B Figure – Solut

Figure – Solubility curves compound II (MTBE/heptane).

Input:

🔅 eurofins

- 1. Organic fraction with 0.6 g of product dissolved in 3 mL MTBE saturated with water.
- Plan to seed form B:
 - 2. Seed at 25 °C.
 - 3. Cool slowly to 0 °C (0.5 °C/min)





Case Study II: MTBE/Heptane Monitoring Form A seeding with Crystalline



ITOTINS



Case Study II: MTBE/Heptane Monitoring Form A seeding with Crystalline





Case Study II: MTBE/Heptane Monitoring Form B seeding with Crystalline



🔅 eurofins



Case Study II: MTBE/Heptane Monitoring Form B seeding with Crystalline





Case Study II Comparison of Form A and B seeding



Form A seeded isolated product PLM images 10x and 40x magnification



Form B seeded isolated product PLM images 10x and 40x magnification



Form A seeded UPLC: 99.83% product Isolated yield: 83.2% Isolated form: Form B

Form B seeded UPLC: 99.74% product Isolated yield: 97.0% Isolated form: Form B

Figure – PXRD patterns of compound II. Form A Simulated from SCXRD | Form B Simulated from SCXRD | Form A seeded product | Form B seeded product

🛟 eurofins

Counts



Case Study II Comparison of Form A and B seeding

Figure – "Crystalline" monitored crystallization of compound II (Form A seeding). **Reactor Temperature** | **Transmittance**



Figure – "Crystalline" monitored crystallization of compound II (Form B seeding).



🛟 eurofins



Case Study II Competitive slurry Form A and B

Figure – PXRD of competitive slurry experiments.

Form A Simulated from SCXRD | Form B Simulated from SCXRD | 50: 50 Form A and B competitive slurry | 10: 90 Form A and B competitive slurry | 90: 10 Form A and B competitive slurry



Mixture of solid Form A and B were stirred for 72 hours in MTBE saturated with water and Compound II

🔅 eurofins



Case Study II Conclusions

- Crystal 16 revealed varying solubilities of Form A and B with and without trace water present. This informs the resulting crystallization protocol.
- In-situ monitoring using Crystalline revealed the different rates of crystal growth upon seeding with either form A or B.
- Induction period for crystal growth when seeding with Form A is likely due to slow growth rate of form A crystals. Spontaneous nucleation of Form B coupled with form conversion to Form B was observed.
- Isolation of Form A from this solvent system may not be possible and is risky.
- Currently still trying to find the right solvent system for large-scale. Many other systems are being explored.

IPrOAc/Heptane IPA/water MeCN/water *etc*.

Conclusions

- Solubility curves from Crystal 16 provide a backbone from which crystallization protocols can be developed.
- Crystalline provides detailed monitoring of the crystallization which helps elucidate the notable events in crystallization, enabling rapid optimization.
- Coupling Crystal 16, and Crystalline, with other inline and offline characterizations enabled rapid crystallization process development
- Much left to learn (particle size distribution, kinetic modelling, etc.)
- Looking forward to the workshop!







Thank You





